Safety Study of BMS-986016 With or Without Nivolumab in Patients With Advanced Solid Tumors

Sponsor
Bristol-Myers Squibb
Study ID
NCT02966548
Phase
PHASE1
Status
Completed

Conditions

  • Cancer

Eligibility Criteria

Sex
ALL
Age
20 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Relatlimab — DRUG
    Specified dose on specified days
  • Nivolumab — DRUG
    Specified dose on specified days

Study Details

This study will be used to determine the safety and tolerability of BMS-986016 administered alone and in combination with Nivolumab in subjects with advanced solid tumors.

Key Dates

Start date
Jan 4, 2017
Status verified
Feb 2025
Primary completion
Jul 9, 2024
Completion
Jul 9, 2024

Study Design

Enrollment
35 participants (actual)
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: Monotherapy
    Relatlimab (BMS-986016) administered every 2 weeks as a single agent intravenous formulation
  • Experimental: Combination Therapy
    Relatlimab (BMS-986016) will be administered in combination with Nivolumab every 2 weeks or every 4 weeks as an intravenous formulation

Primary Outcome Measure

Number of adverse events (AE) [ Time Frame: Approximately 2.2 years ]

Related Studies